Concurrent Administration of RSV and Influenza Vaccines Appears Safe in Healthy Older Adults

In a randomized, double-blind Australian study, antibody responses and likelihood of adverse events were similar whether the two vaccines were coadministered or given sequentially.

Respiratory syncytial virus (RSV) vaccination is now recommended, with shared decision-making, for adults aged ≥60. As both RSV and influenza are seasonal infections; coadministration of these vaccines has been proposed to eliminate the need for a second healthcare visit. However, concerns have been raised that this approach could blunt the immune response to both vaccines while also causing higher rates of adverse events. In a manufacturer-supported, randomized, double-blind trial from April to October of 2022, Australian investigators compared concurrent versus sequential administration of the bivalent prefusion F glycoprotein RSV vaccine (ABRYSVO™) and the quadrivalent seasonal inactivated influenza vaccine (Fluad Quad), with each vaccin…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Concurrent Administration of RSV and Influenza Vaccines Appears Safe in Healthy Older Adults

Topics

Reviewing Author